SCHEMBL2599720

SCHEMBL2599720

Cc1cc(Cl)cc2c(C=O)cn(C3CC3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.39
TOP2A P11388 2/20 0.34
TOP2B Q02880 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
MPI P34949 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KRAS P01116 1/20 0.32
ERN1 O75460 1/20 0.32
PDE10A Q9Y233 1/20 0.31
CNR2 P34972 1/20 0.31
BRD4 O60885 1/20 0.31
BRD2 P25440 1/20 0.31
BRD3 Q15059 1/20 0.31
CYP1A2 P05177 1/20 0.31
HTR3A P46098 1/20 0.31
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599816 0.83 ALDH1A1 (0.39) ALDH1A1LMNATOP2ATOP2BKDM4E
SCHEMBL12182235 0.82 ALDH1A1 (0.38) ALDH1A1LMNA
SCHEMBL12182211 0.77 TRIM24 (0.40) ALDH1A1LMNATOP2ATOP2BKDM4E
SCHEMBL2599740 0.75 ALDH1A1 (0.37) ALDH1A1LMNAKDM4EMEN1MAPT
SCHEMBL2599778 0.71 ALDH1A1 (0.36) ALDH1A1LMNA
SCHEMBL2599750 0.71 ALDH1A1 (0.39) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL6871385 0.69 POLB (0.38) ALDH1A1LMNAMEN1MAPTKMT2A
SCHEMBL2599786 0.67 ALDH1A1 (0.33) ALDH1A1LMNA
SCHEMBL29954963 0.66 TOP2A (0.37) ALDH1A1LMNATOP2ATOP2B
SCHEMBL28684693 0.65 PTPN1 (0.40) KDM4EMEN1MAPTKMT2AERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571356-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2013-03-27 EP disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS SSTR5, SSTR2, SSTR1 ALDH1A1 1103/4885LMNA 1256/4885TOP2A 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.